302 related articles for article (PubMed ID: 10779788)
1. Synthetic endotoxin-binding peptides block endotoxin-triggered TNF-alpha production by macrophages in vitro and in vivo and prevent endotoxin-mediated toxic shock.
Dankesreiter S; Hoess A; Schneider-Mergener J; Wagner H; Miethke T
J Immunol; 2000 May; 164(9):4804-11. PubMed ID: 10779788
[TBL] [Abstract][Full Text] [Related]
2. Comparison of endotoxin antagonism of linear and cyclized peptides derived from limulus anti-lipopolysaccharide factor.
Leslie DB; Vietzen PS; Lazaron V; Wasiluk KR; Dunn DL
Surg Infect (Larchmt); 2006 Feb; 7(1):45-52. PubMed ID: 16509785
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal and endotoxin neutralizing activity of a peptide derived from Limulus antilipopolysaccharide factor.
Weiss CA; Wasiluk KR; Kellogg TA; Dunn DL
Surgery; 2000 Aug; 128(2):339-44. PubMed ID: 10923014
[TBL] [Abstract][Full Text] [Related]
4. Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro.
Battafaraono RJ; Dahlberg PS; Ratz CA; Johnston JW; Gray BH; Haseman JR; Mayo KH; Dunn DL
Surgery; 1995 Aug; 118(2):318-24. PubMed ID: 7638748
[TBL] [Abstract][Full Text] [Related]
5. A Limulus antilipopolysaccharide factor-derived peptide exhibits a new immunological activity with potential applicability in infectious diseases.
Vallespi MG; Glaria LA; Reyes O; Garay HE; Ferrero J; Araña MJ
Clin Diagn Lab Immunol; 2000 Jul; 7(4):669-75. PubMed ID: 10882670
[TBL] [Abstract][Full Text] [Related]
6. High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant Limulus anti-lipopolysaccharide factor.
Ried C; Wahl C; Miethke T; Wellnhofer G; Landgraf C; Schneider-Mergener J; Hoess A
J Biol Chem; 1996 Nov; 271(45):28120-7. PubMed ID: 8910426
[TBL] [Abstract][Full Text] [Related]
7. A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo.
Jiang Z; Hong Z; Guo W; Xiaoyun G; Gengfa L; Yongning L; Guangxia X
Int Immunopharmacol; 2004 Apr; 4(4):527-37. PubMed ID: 15099530
[TBL] [Abstract][Full Text] [Related]
8. A synthetic cyclic peptide derived from Limulus anti-lipopolysaccharide factor neutralizes endotoxin in vitro and in vivo.
Ren JD; Gu JS; Gao HF; Xia PY; Xiao GX
Int Immunopharmacol; 2008 Jun; 8(6):775-81. PubMed ID: 18442780
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial cathelicidin polypeptide CAP11 suppresses the production and release of septic mediators in D-galactosamine-sensitized endotoxin shock mice.
Murakami T; Obata T; Kuwahara-Arai K; Tamura H; Hiramatsu K; Nagaoka I
Int Immunol; 2009 Aug; 21(8):905-12. PubMed ID: 19556302
[TBL] [Abstract][Full Text] [Related]
10. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells.
Nagaoka I; Hirota S; Niyonsaba F; Hirata M; Adachi Y; Tamura H; Heumann D
J Immunol; 2001 Sep; 167(6):3329-38. PubMed ID: 11544322
[TBL] [Abstract][Full Text] [Related]
11. Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock.
Alpert G; Baldwin G; Thompson C; Wainwright N; Novitsky TJ; Gillis Z; Parsonnet J; Fleisher GR; Siber GR
J Infect Dis; 1992 Mar; 165(3):494-500. PubMed ID: 1538154
[TBL] [Abstract][Full Text] [Related]
12. A novel endotoxin antagonist attenuates tumor necrosis factor-alpha secretion.
Dahlberg PS; Acton RD; Battafarano RJ; Uknis ME; Ratz CA; Johnston JW; Haseman JR; Gray BH; Dunn DL
J Surg Res; 1996 Jun; 63(1):44-8. PubMed ID: 8661170
[TBL] [Abstract][Full Text] [Related]
13. An anti-endotoxin peptide that generates from the amino-terminal domain of complement regulatory protein C1 inhibitor.
Zhang H; Li J; Barrington RA; Liang G; Qin G; Liu DX
Biochem Biophys Res Commun; 2007 Jul; 359(2):285-91. PubMed ID: 17543887
[TBL] [Abstract][Full Text] [Related]
14. Binding specificity of polymyxin B, BPI, LALF, and anti-deep core/lipid a monoclonal antibody to lipopolysaccharide partial structures.
Kellogg TA; Lazaron V; Wasiluk KR; Dunn DL
Shock; 2001 Feb; 15(2):124-9. PubMed ID: 11220640
[TBL] [Abstract][Full Text] [Related]
15. Augmentation of the lipopolysaccharide-neutralizing activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by replacement with hydrophobic and cationic amino acid residues.
Nagaoka I; Hirota S; Niyonsaba F; Hirata M; Adachi Y; Tamura H; Tanaka S; Heumann D
Clin Diagn Lab Immunol; 2002 Sep; 9(5):972-82. PubMed ID: 12204946
[TBL] [Abstract][Full Text] [Related]
16. Design of a potent novel endotoxin antagonist.
Uknis ME; Wasiluk KR; Acton RD; Klaerner HG; Dahlberg PS; Ilyina EE; Haseman JR; Gray BH; Mayo KH; Dunn DL
Surgery; 1997 Aug; 122(2):380-5. PubMed ID: 9288144
[TBL] [Abstract][Full Text] [Related]
17. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality.
Solorzano CC; Ksontini R; Pruitt JH; Auffenberg T; Tannahill C; Galardy RE; Schultz GP; MacKay SL; Copeland EM; Moldawer LL
Shock; 1997 Jun; 7(6):427-31. PubMed ID: 9185243
[TBL] [Abstract][Full Text] [Related]
18. Globin attenuates the innate immune response to endotoxin.
Yang H; Wang H; Bernik TR; Ivanova S; Wang H; Ulloa L; Roth J; Eaton JW; Tracey KJ
Shock; 2002 Jun; 17(6):485-90. PubMed ID: 12069185
[TBL] [Abstract][Full Text] [Related]
19. A novel synthetic lipid A analog with low endotoxicity, DT-5461, prevents lethal endotoxemia.
Sato K; Yoo YC; Fukushima A; Saiki I; Takahashi TA; Fujihara M; Tono-Oka S; Azuma I
Infect Immun; 1995 Aug; 63(8):2859-66. PubMed ID: 7622206
[TBL] [Abstract][Full Text] [Related]
20. Endotoxin-binding synthetic peptides with endotoxin-neutralizing, antibacterial and anticoagulant activities.
Hirata M; Shimomura Y; Yoshida M; Wright SC; Larrick JW
Prog Clin Biol Res; 1994; 388():147-59. PubMed ID: 7831355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
